PLIANT THERAPEUTICS INC (PLRX) Stock News
NASDAQ:PLRX - Nasdaq - US7291391057 - Common Stock - Currency: USD
PLRX Latest News, Press Relases and Analysis
Unusual volume stocks in Wednesday's session
Discover the stocks with unexpected trading volume in today's session on the US markets.
Which stocks are experiencing notable movement on Monday?
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Pliant Therapeutics, Inc ("Pliant" or the "Company") (NASDAQ: PLRX). Such...
PLRX Investors Have Opportunity to Join Pliant Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
Pliant Therapeutics Announces Next Steps Following DSMB Recommendation on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis
Pliant has initiated assembly of outside panel of world-renowned experts to review BEACON-IPF trial data
Let's have a look at the top gainers and losers in the middle of the day of today's session.
Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session.
The market is filled with gapping stocks in Monday's session.
Let's delve into the US markets on Monday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
Monday's pre-market session: top gainers and losers
Discover the top movers in Monday's pre-market session and stay informed about market dynamics.
Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis
Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis
Following DSMB recommendation, the Company has voluntarily paused enrollment and dosing in the BEACON-IPF Phase 2b trial and will monitor current patients...
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced that on January 21, 2025, it...
Pliant Therapeutics Appoints Delphine Imbert, Ph.D. as Chief Technical Officer
Pliant Therapeutics Appoints Delphine Imbert, Ph.D. as Chief Technical Officer
Dr. Imbert brings 25 years of strategic clinical to commercial-stage manufacturing and drug development experience SOUTH SAN FRANCISCO, Calif., Jan. 22,...
Pliant Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Pliant Therapeutics to Participate in Upcoming Investor Events
Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024
Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024
INTEGRIS-PSC featured in an oral late breaker presentation SOUTH SAN FRANCISCO, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc....
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Pliant Therapeutics to Participate in the Stifel Healthcare Conference
Pliant Therapeutics Appoints Gary Palmer, M.D. as Senior Vice President of Medical Affairs
Pliant Therapeutics Appoints Gary Palmer, M.D. as Senior Vice President of Medical Affairs
Former Bristol Myers Squibb Global Medical Affairs Lead brings over 25 years of experience to Pliant SOUTH SAN FRANCISCO, Calif., Oct. 01, 2024 (GLOBE...
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced that on September 30, 2024 it...